Nitrolingual Pompspray (Glyceryl Trinitrate)

Glyceryl trinitrate releases nitric oxide, which activates guanylate cyclase in vascular smooth muscle. This raises cyclic GMP levels, causing relaxation of veins and arteries, reducing cardiac preload and afterload, and lowering myocardial oxygen demand.

The specific dose and frequency of Nitrolingual Pompspray are determined by the prescribing clinician based on the patient’s condition, severity of angina, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for glyceryl trinitrate in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nitrolingual Pompspray is an organic nitrate, offering rapid onset of action via oromucosal delivery. Compared with oral tablets, the spray provides quicker relief, while other classes such as beta‑blockers or calcium‑channel blockers act through different mechanisms and may be used in combination for comprehensive angina management.

Store Nitrolingual Pompspray at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and avoid freezing to maintain product stability.

The spray is applied to the oral mucosa, typically under the tongue or inside the cheek, as directed by the prescriber. The patient should avoid swallowing immediately, allowing the medication to absorb through the mucous membranes for rapid effect.

Serious risks include severe hypotension, syncope, methemoglobinemia, and allergic reactions such as rash or bronchospasm. Patients should be monitored for these events, especially when initiating therapy or when used with other vasodilators.

Nitrolingual Pompspray should be avoided in patients with known hypersensitivity to glyceryl trinitrate or other nitrates, those with severe hypotension, and individuals concurrently using phosphodiesterase‑5 inhibitors unless specifically directed by a physician.